BCDA

BioCardia, Inc. [BCDA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BCDA Stock Summary

Top 10 Correlated ETFs

BCDA

Top 10 Correlated Stocks

BCDA

In the News

BCDA Financial details

Company Rating
-
Market Cap
10.42M
Income
-11.56M
Revenue
477K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-1.12
Forward P/E
-
PEG
0.61
P/S
24.65
P/B
-21.29
P/C
-
P/FCF
-1.26
Quick Ratio
0.58
Current Ratio
0.64
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.55
EPS next Y
-
EPS next Q
-
EPS this Y
-17.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-26.87%
Revenue last 5Y
-7.65%
Revenue Q/Q
-96.36%
EPS Q/Q
-27.08%
-
-
-
-
SMA20
-18.35%
SMA50
-25.21%
SMA100
-35.04%
Inst Own
-
Inst Trans
-
ROA
-334%
ROE
-645%
ROC
-30.11%
Gross Margin
-1988%
Oper. Margin
-2202%
Profit Margin
-2198%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.36-2.92
52W High
-
52W Low
-
RSI
43.49
Rel Volume
2.86
Avg Volume
391.7K
Volume
1.12M
Perf Week
0.62%
Perf Month
-22.81%
Perf Quarter
-31.25%
Perf Half Y
-40.14%
-
-
-
-
Beta
1.489
-
-
Volatility
0.07%, 0.1%
Prev Close
10.68%
Price
0.88
Change
11.11%

Something similar

Top by Market Cap
BRK-B
MSFT
FB2A.DE
TSLA
M&M.NS
Top Correlated ETFs
BKLN
2806.HK
2824.HK
3110.HK
CHIQ
Top Correlated Stocks
ORIENTLTD.NS
LGBBROSLTD.NS
ORIENTALTL.NS
0215.HK
600663.SS
Similar Market Cap
STABL.ST
GIQU.TO
LMFA
MBO.L
LCOP.L

Company Profile

Healthcare Biotechnology
  • Volume Average 391.7K
  • Market Capitalization 10.42M
  • Employee 16
  • CEO Dr. Peter A. Altman Ph.D.
  • Headquarters Sunnyvale,CA,US
  • IPO Date 1996-11-13
  • Website https://www.biocardia.com

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.